Goldman Sachs Initiates Coverage On Exscientia with Buy Rating, Announces Price Target of $30
Goldman Sachs analyst Chris Shibutani initiates coverage on Exscientia (NASDAQ:EXAI) with a Buy rating and announces Price Target of $30.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
Exscientia Announces Publication of EXALT-1 Trial In Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform To Improve Cancer Treatment Outcomes
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers
54% of patients demonstrated a
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)
List Of IPOs For Friday, Oct. 1, 2021: MTRYU, FWRG, EXAI, GATEU, DMYS.U, TDCX
Monterey Bio Acquisition (MTRYU)
First Watch Restaurant Group (FWRG)
Exscientia (EXAI)
Marblegate Acquisition (GATEU)
dMY Technology Group VI (DMYS.U)
TDCX (TDCX)
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)